Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV [6]
Journal
New England Journal of Medicine
Journal Volume
357
Journal Issue
16
Date Issued
2007
Author(s)
SDGs
Other Subjects
peginterferon alpha2a; ribavirin; genotype; hepatitis C; Hepatitis C virus; human; letter; priority journal; recurrence risk; statistical significance; treatment duration; virotherapy; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Interferon Alfa-2a; Polyethylene Glycols; Recurrence; Ribavirin; Viral Load
Type
letter